ISSN:
1432-0584
Schlagwort(e):
Teniposide
;
VM-26
;
Chronic lymphocytic leukemia
Quelle:
Springer Online Journal Archives 1860-2000
Thema:
Medizin
Notizen:
Summary Teniposide has been evaluated in a phase II clinical trial in chronic lymphocytic leukemia (CLL). Among 16 consecutive patients with CLL entered in the study and treated with Teniposide, 100 mg/m2 weekly, no objective response was observed. Toxicity was generally mild and mainly hematologic. Teniposide at this dosage and schedule is an inactive drug in CLL.
Materialart:
Digitale Medien
URL:
http://dx.doi.org/10.1007/BF00320143
Permalink